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ABSTRACT 
AMP-activated protein kinase (AMPK) is a metabolic stress-sensing kinase. We previously showed that 
glucose deprivation induces autophosphorylation of AMPKβ at threonine-148 (Thr-148), which prevents 
the binding of AMPK to glycogen. Furthermore, in MIN6 cells, AMPKβ1 binds to R6 (PPP1R3D), a 
glycogen-targeting subunit of protein phosphatase 1 (PP1), thereby regulating the glucose-induced 
inactivation of AMPK. Here, we further investigated the interaction of R6 with AMPKβ and the possible 
dependency on Thr-148 phosphorylation status. Yeast two-hybrid analyses and co-immunoprecipitation of 
the overexpressed proteins in HEK293T cells revealed that both AMPKβ1 and β2 wild-type (WT) 
isoforms bind to R6. The AMPKβ/R6 interaction was stronger with the muscle-specific β2-WT and 
required association with the substrate-binding motif of R6. When HEK293T cells or C2C12 myotubes 
were cultured in high-glucose medium, AMPKβ2-WT and R6 weakly interacted. In contrast, glycogen 
depletion significantly enhanced this protein interaction. Mutation of AMPKβ2 Thr-148 prevented the 
interaction with R6 irrespective of the intracellular glycogen content. Treatment with the AMPK activator 
oligomycin enhanced AMPKβ2/R6 interaction in conjunction with increased Thr-148 phosphorylation in 
cells grown in low glucose medium. These data are in accordance with R6 binding directly to AMPKβ2 
when both proteins detach from the diminishing glycogen particle, which is simultaneous to increased 
AMPKβ2 Thr-148 autophosphorylation. Such model points to a possible control of AMPK by PP1-R6 
upon glycogen depletion in muscle. 
 
SUMMARY STATEMENT 
Breakdown of intracellular glycogen enhances interaction of the AMPKβ2 subunit and the R6 glycogen-
targeting subunit of the protein phosphatase-1 (PP1), which occurs in conjunction with increased β2-
threonine-148 phosphorylation. 
 
SHORT TITLE 
Glycogen-dependent regulation of AMPKβ2/R6 interaction 
 
KEYWORDS 
AMP-activated protein kinase (AMPK), R6, glycogen targeting, protein-protein interaction, 
phosphorylation, glycogen metabolism 
 
  
 
  
ABBREVIATIONS 
ACC, Acetyl-CoA Carboxylase; AICAR, 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK, 
AMP-activated protein kinase; ATP, adenosine triphosphate; β-CD, β-cyclodextrin; CBM, Carbohydrate-
binding module; EV, empty vector; GP, Glycogen phosphorylase; GS, Glycogen synthase; HEK293T, 
human embryonic kidney 293T cell line; iFCS, heat-inactivated calf serum; IP, Immunoprecipitation; PP1, 
Protein phosphatase type1; R6, PP1-glycogen-targeting subunit PPP1R3D; Snf1, sucrose-non-fermenting 
1; Reg1, yeast targeting subunit of PP1; WT, wild-type; Y2H, Yeast two-hybrid. 
 
 
INTRODUCTION 
Muscular tissue, in particular skeletal muscle, is an important site for glucose storage. It has become 
evident that glucose disposal into glycogen is essential for coordinated glucose homeostasis, as conditions 
limiting glycogen synthesis are associated with, for instance, hyperglycemia and insulin resistance (1). 
AMP-activated protein kinase (AMPK) is a metabolic energy sensor that mediates insulin-independent 
GLUT4 translocation to the plasma membrane resulting in increased glucose uptake (2). Therefore, 
AMPK activation could normalize blood glucose levels in type 2 diabetic patients. In response to various 
cellular stresses (e.g., contraction, nutrient-deprivation), AMPK is activated and modulates downstream 
targets to induce catabolic, ATP-producing processes and inhibit anabolic, ATP-consuming processes, 
thereby restoring energy homeostasis. AMPK consists of three subunits, the catalytic α subunit, and two 
regulatory β and γ subunits; the latter are essential for regulating AMPK activity, as well as subcellular 
localization. AMPK subunits occur in different isoforms (α1, α2; β1, β2; γ1, γ2, γ3) partly showing a 
tissue-specific expression pattern. Namely, β2 is the predominant isoform found in heart and skeletal 
muscle (3, 4). Accordingly, it has been reported that β1 knockout mice have a minimal phenotype in 
skeletal muscle (5), whereas β2 knockout mice have reduced skeletal muscle AMPK activity, exercise 
capacity and glucose uptake (6, 7).  
AMPK is known to shuttle between the nucleus (8, 9) and the cytoplasm (10, 11), suggesting that 
AMPK exerts compartment-specific effects in order to monitor and coordinate complex cell biological 
processes. The β subunit carbohydrate-binding module (CBM) allows AMPK to associate with glycogen 
(12, 13), where it interacts with other glycogen-binding proteins including glycogen synthase (GS) (13) 
and glycogen phosphorylase (GP) (12). Notably, β2 shows higher affinity for glycogen compared to β1 
(14). Acute 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR)-induced AMPK activation 
inactivates GS via Ser7 phosphorylation in skeletal muscle (15), although high levels of glucose-6-
phosphate can override this inhibition (16).  
The regulation of the activity status of localized AMPK is dependent on allosteric 
activation/repression and the action of upstream kinases capable of phosphorylating threonine-172 (Thr-
172) in the catalytic α subunit (e.g., LKB1, TAK1, CaMKK2).  Several protein phosphatases (e.g., PP1, 
PP2A, PP2C) dephosphorylate Thr-172, thus leading to AMPK inactivation. PP1 is an important protein 
phosphatase in mammalian cells that is involved in proper coordination of glycogen metabolism by 
dephosphorylating target enzymes such as GS and GP. Recruitment of PP1 to its target substrates and to 
glycogen occurs by means of its glycogen-targeting proteins, such as PTG/R5 (PPP1R3C) (17) or R6 
(PPP1R3D) (18, 19). Insight into PP1-mediated AMPK regulation came from our previous study (20), 
which showed that R6 physically interacts with the AMPKβ1 subunit, resulting in glucose-induced AMPK 
dephosphorylation by the PP1-R6 complex. Furthermore, we found that the CBM domain within the 
AMPKβ1 subunit is required for interaction with R6, as substitution of glycine-147 for arginine (G147R) 
resulted in total loss of AMPK/R6 interaction (20). These results were consistent with parallel studies in 
yeast showing that Snf1 is regulated by glucose, and that Gal83 via its CBM interacts with Reg1, the 
orthologs of AMPKβ and R6, respectively (21), thus pointing to an evolutionary conserved mechanism. 
We recently reported that autophosphorylation of Thr-148 in the AMPKβ subunit interferes with 
the recruitment of AMPK to glycogen, suggesting that AMPK-glycogen localization is tightly regulated 
and linked to glycogen storage (22). Given the direct binding of AMPKβ1 to R6 and the observed loss of 
this interaction using the AMPKβ1-G147R mutant, we hypothesized a role for AMPKβ Thr-148 
 phosphorylation. In this current study, we provide insight into the binding of AMPKβ2 to R6 in relation to 
glycogen content and AMPKβ2 Thr-148 phosphorylation. Our results indicate that the AMPKβ2/R6 
interaction is dynamically controlled by glycogen content. 
 
MATERIALS AND METHODS 
Plasmids 
For expression in mammalian cells, the cDNA of full-length AMPKβ1 and AMPKβ2 was amplified by 
PCR and ligated in frame into the pmCherry expression vector (Clontech) via EcoRI and SalI restriction 
sites, as previously described (22). An AMPKβ2–mCherry construct bearing a threonine-to-aspartate 
mutation on residue 148 (T148D) was generated using the Quick-change site-directed mutagenesis kit 
(Stratagene). The pcDNA3 constructs for expression of AMPKγ1 and myc-AMPKα1 were kindly 
provided by Dr. D. Carling (Imperial College London, London, United Kingdom). The corresponding 
ORF of AMPKβ2-T148D mutant was subcloned into pBTM116 to allow for expression in yeast (LexA-
AMPKβ2-T148D). The pFLAG-R6 construct for mammalian expression of R6-WT and R6-mutants (R6-
RARA, -RAHA, -WDNAD and -WANNA) were generated as previously described, and the pFLAG was 
used as empty vector (EV) control (20, 23). 
Other plasmids used for yeast two-hybrid analyses were pGADT7-Φ (GAD, empty plasmid), 
pGADT7-R6 (GAD-R6), pBTM-R6 (LexA-R6), pBTM-R6-RARA (LexA-R6-RARA), pBTM-R6-RAHA 
(LexA-R6-RAHA), pBTM-R6-WANNA (LexA-R6-WANNA), pBTM-R6-WDNAD (LexA-R6-
WDNAD), pGADT7-AMPKβ1 (GAD-AMPKβ1), pGADT7-AMPKβ2 (GAD-AMPKβ2), pBTM-
AMPKβ1 (LexA-AMPKβ1), pBTM-AMPKβ2 (LexA-AMPKβ2) (20, 23-25). 
For retroviral overexpression and optimal detection of exogenous β2, full-length AMPKβ2-WT or 
AMPKβ2-T148D was amplified using PCR primers containing an optimized tetra-cysteine sequence 
(FlAsH-tag; FLNCCPGCCMEP). First, the corresponding ORF (FlAsH-tag) was subcloned into the SalI 
and NotI site of the mammalian β2-WT-mCherry or β2-T148D-mCherry construct, exchanging the 
mCherry-tag for FlAsH-tag. Second, β2-WT-FlAsH or β2-T148D-FlAsH was amplified and subcloned 
into the EcorI and SalI site of the retroviral pBabe-puromycin retroviral backbone (kindly provided by Dr. 
G. Nolan, Stanford University, CA). 
 For retroviral overexpression of R6, the corresponding ORF (R6-WT) was amplified by PCR and 
subcloned into the BstxI and SalI restriction sites of the pBabe-puromycin retroviral backbone (kindly 
provided by Dr. G. Nolan, Stanford University, CA). The pBabe-puromycin empty vector (EV) was used 
as control. Primer sequences are available from the author upon request. All of the constructs were 
verified by DNA sequencing.  
 
Cell culture 
The human embryonic kidney 293T cell line (HEK293T) was cultured in DMEM with high glucose (25 
mM) (Gibco), supplemented with 10 % (v/v) heat-inactivated fetal calf serum (iFCS, Bodinco BV, 
Alkmaar, The Netherlands) and 1 % penicillin/streptomycin (Invitrogen), unless otherwise stated. For 
transient transfections, HEK293T cells were seeded to 30 % confluence in 6-well plates (Greiner Bio-one) 
24 h before transfection. For determination of protein-protein interaction, cells were co-transfected with 
AMPK (α1-myc, γ1, and β1-WT-mCherry or β2-WT/β2-T148D-mCherry), and/or FLAG-R6 (R6-WT/R6-
RARA/R6-RAHA/R6-WANNA/R6-WDNAD) or FLAG empty vector (EV) plasmid DNA using 
Lipofectamine 2000 (Invitrogen) in antibiotic-free culture medium. Six to eight hours after transfection, 
transfection medium was replaced by normal growth medium. At 48-72 h after transfection and 
continuous culturing (i.e., without change of medium), cells were harvested for glycogen or subjected to 
immunoprecipitation and Western blotting.  
In order to induce glycogen depletion, HEK293T cells growing in high glucose medium (DMEM 
25 mM glucose, 10 % iFCS), were subjected to forskolin treatment (100 µM, Sigma), low glucose 
medium (DMEM 3 mM glucose, 10 % iFCS), or glucose-deprived medium (DMEM 0 mM, 10 % iFCS) 
for 16 h. To activate AMPK, cells were serum-starved in high- (DMEM 25 mM) or low-glucose (3 mM) 
medium for 16 h, and subsequently treated with oligomycin (3 μM, Sigma) for 1 h.  
 The mouse skeletal muscle cell line C2C12 was kindly provided by Dr. R.C. Langen (Maastricht 
University, The Netherlands). C2C12 cells were continuously cultured to approximately 80 % confluence 
in DMEM with high glucose (25 mM) (Gibco), supplemented with 10 % (v/v) iFCS (Bodinco BV, 
Alkmaar, The Netherlands) and 1 % penicillin/streptomycin (Invitrogen). For differentiation into 
myotubes, myocytes (75 - 85 % confluence) were further grown in differentiation medium (DMEM 25 
mM glucose (Gibco), supplemented with 2 % heat-inactivated horse serum (Invitrogen, Life 
Technologies) and 1 % penicillin/streptomycin (Invitrogen) for  4 – 5 days. Subsequently, cells were used 
in the corresponding experiments. In order to induce glycogen depletion, myotubes were maintained in 
low glucose medium (DMEM 3 mM glucose, supplemented with 2 % iFCS), for 16 h. In order to activate 
AMPK, myotubes were maintained in high or low glucose for 16 hours as described above, and 
subsequently treated with oligomycin (5 μM, Sigma) for 30 min.  
 
Retroviral infections 
In order to study protein-protein interactions in C2C12 myotubes, growing cells were infected with 
FlAsH-tagged AMPKβ2-WT or -T148D, or FLAG-tagged R6 retrovirus. Briefly, retroviral systems and 
Phoenix helper-free retrovirus producer cell lines were used as published before (26-28). Amphotropic 
retroviral supernatants were produced as previously described (22). Briefly, 24 - 48 h after calcium 
phosphate/DNA transfection of producer cells, supernatants were harvested, filtered (0.45 micron filters; 
Corning, Germany) and used for infection of C2C12 cells in presence of 4 µg/ml polybrene (Sigma). For 
infections, cells were incubated with virus particles for 6 - 8 h and then allowed to recover for 48 h on 
fresh medium, before selection pressure was applied. Stably infected cells were selected 2 days post-
infection with 4 μg/ml puromycin for 36 – 48 h preceding experiments.  
 
Immunoprecipitation and Western blotting 
Immunoprecipitation procedures were performed as previously described (22). Briefly, exogenous myc-
AMPKα1 was immunoprecipitated using anti-myc-tag antibody (9B11, Cell Signaling Technology, 
Beverly, MA), exogenous R6 was immunoprecipitated using anti-FLAG-tag antibody (F3165, Sigma), 
and endogenous AMPK was immunoprecipitated using a combination of AMPKα1 and AMPKα2 
antibodies raised in sheep (kindly provided by Prof. dr. G. Hardie), followed by incubation with protein 
G-Sepharose beads (GE Healthcare). Western blot analysis was carried out using the following primary 
antibodies: myc-tag, tAMPKα, AMPKβ1, AMPKβ2, phospho-AMPK-T172 (all from Cell Signaling 
Technology, Beverly, MA), FLAG-tag (F3165, Sigma), R6 (AP13440a, Abgent), and phospho-AMPKβ2-
T148 (22). R6 was detected using FLAG-tag (F3165, Sigma), unless otherwise stated. Detection was 
performed according to its primary antibody using anti-rabbit (Cell Signaling Technology) and anti-mouse 
(Dako) horse-radish peroxidase (HRP)-conjugated secondary antibodies, followed by chemiluminescence.  
In order to investigate the role of glycogen, myc-AMPKα1 was immunoprecipitated using the 
anti-myc-tag antibody after the addition of the glycogen-mimic β-cyclodextrin (5 mM, Sigma) for 1 h at 4 
°C. Subsequently, immune complexes were electrophoresed by SDS-PAGE and analyzed by Western blot 
analysis, as described above. 
 
Biochemical intracellular glycogen measurement 
Intracellular glycogen content was measured, as previously described (22). Briefly, HEK293T cells (non-
transfected or transfected) or stably-infected C2C12 myotubes were lysed in potassium hydroxide (30 %) 
and boiled at 70 °C for 30 min. Subsequently, samples were cooled to 25 °C before sodium sulfate (6 %, 
w/v) and EtOH (99.5 %, v/v) were added at a 1:1:3 ratio. After thorough mixing, samples were rotated 
top-over-top at 4 °C for 30 – 60 min. The precipitate was collected by centrifugation at 5000 rpm 
(Eppendorf Centrifuge 5415 R) for 5 min at 4 °C. To hydrolyze glycogen, pellets were dissolved in 1 M 
HCl and boiled at 100 °C for 2 h. Samples were cooled before neutralization using 2 M NaOH. 
Hydrolysates were used for glucose determination using a glucose (GO) assay kit (Sigma), according to 
the manufacturer’s instructions. 
 
 Determination of glucose uptake  
The glucose uptake protocol was adapted from earlier work (29). Briefly, stably infected C2C12 myotubes 
were incubated with the uptake buffer containing deoxy-D-glucose (4 μM), with tracer amounts of 3H-
labelled 2-deoxy-D-glucose, for 10 min. Surplus substrate was removed by washing the cells with ice-cold 
uptake buffer and cells were lysed in 0.1 N sodium hydroxide. Incorporated glucose was assessed by 
scintillation counting of 3H in lysates.  
 
Preparation of skeletal muscle tissue homogenates 
Gastrocnemius muscle was taken from one female wild type C57/BL6 mouse of the regular Maastricht 
University breeding program. After sacrifice by carbon dioxide inhalation and cervical dislocation, tissues 
were freeze clamped between aluminum tongs precooled in liquid nitrogen and stored at -80°C until 
analysis. Muscle extract was prepared essentially as previously described (30). Briefly, the tissue sample 
was extracted in SET buffer (250 mM Sucrose, 2 mM EDTA, 10 mM Tris, pH 7.4) in the presence of 
protease and phosphatase inhibitors (Complete and PhosStop; Roche) by homogenization and ultrasound 
treatment, followed by centrifugation. Supernatant was used for immunoprecipitation (see above) using 
the indicated antibodies. 
 
Yeast two-hybrid (Y2H) analyses 
Yeast two-hybrid analysis was performed as previously described (20, 24). Briefly, interaction analysis 
using yeast THY-AP4 strain (MATa, ura3, leu2, lexA::lacZ::trp1, lexA::HIS3, lexA::ADE2) co-
transformed with the indicated combination of plasmids (see above). Transformants were grown in 
selective 4 % glucose synthetic complete medium lacking the corresponding supplements to maintain 
selection for plasmids. The strength of the interaction was determined by measuring β-galactosidase 
activity in permeabilized yeast cells and expressed in Miller units. In all Y2H analyses similar protein 
levels were obtained from the expression constructs, as verified in the crude extracts from the different 
yeast transformants. 
 
Statistical analysis 
All bar graph data are presented as mean ± S.E.M., unless otherwise stated. Statistical differences were 
evaluated using unpaired Student's t test and statistical analysis software Prism 4 (GraphPad Software, 
Inc.). P values equal to or less than 0.05 were considered statistically significant. 
 
 
RESULTS 
R6 preferentially interacts with AMPKβ2 
We previously demonstrated that R6 (PPP1R3D), one of the glycogen-targeting subunits of the protein 
phosphatase 1 (PP1), physically interacts with AMPKβ1 in MIN6 pancreatic β cells (20). To verify 
AMPKβ1/R6 interaction in HEK293T cells, we overexpressed myc-tagged AMPK 
heterotrimers (myc-α1, β1-mCherry, γ1), together with FLAG-tagged R6 (FLAG-R6) or empty vector 
control (EV). Physical interaction between AMPKβ1 and R6 was assessed by immunoprecipitation (IP) of 
AMPK from cells that were routinely cultured under glucose-rich conditions (25 mM glucose) (Fig. 1A). 
Pull-down of myc-AMPKα1 resulted in co-immunoprecipitation of both mCherry-tagged AMPKβ1 (65 
kD) and FLAG-tagged R6, indicating formation of the heterotrimeric AMPK complex and the interaction 
with R6 (Fig. 1A). As expected, FLAG-R6 signal was absent in cells transfected with EV. Next, we 
investigated the interaction between muscle-specific AMPKβ2 heterotrimers (myc-α1, β2-mCherry, γ1) 
and R6 (FLAG-R6) using co-transfection and immunoprecipitation in HEK293T. As both proteins co-
immunoprecipitated, this data points to the occurrence of a physical interaction between R6 and AMPKβ2 
(Fig. 1B). Interestingly, co-immunoprecipitation appeared stronger in the presence of the AMPKβ2 
compared to β1. These data were further confirmed by yeast-two-hybrid (Y2H) analyses: in Fig. 1C it is 
shown that R6 binds to both AMPKβ1 and β2, while the interaction between AMPKβ2 and R6 is 
 significantly stronger than the one between AMPKβ1 and R6. Combined, these findings suggest that R6 
prefers interaction with AMPKβ2 over AMPKβ1. 
 
R6 interaction with AMPKβ2 requires its substrate-binding motif 
Recently, a number of functionally distinct protein domains have been identified in the R6 glycogen-
targeting subunit of PP1 (23). R6 is composed of domains that mediate binding to carbohydrates (via its 
CBM), binding to the PP1 catalytic subunit (PP1c; RVXF motif), and to the glycogen metabolism-related 
substrates of PP1 (via the highly conserved WDNND motif). To investigate whether and which of these 
motifs are involved in the interaction between the AMPKβ subunit and R6, we performed studies in 
HEK293T cells co-expressing AMPKβ2 complex (myc-α1, β2-mCherry, γ1) with FLAG-R6, the latter 
carrying various mutations corresponding to its protein motifs (23) (Fig. 2A, B). We again 
immunoprecipitated myc-AMPKα1 using a myc-directed antibody. Of note, endogenous R6 was not 
detected either in lysate or in immunoprecipitated material, thereby substantiating the need for FLAG-R6 
overexpression to study the interaction between AMPKβ2 and R6 (Fig. 2B: EV condition). R6 carried 
various domain-specific mutations: in both R6-RARA and R6-RAHA mutants, the hydrophobic valine 
and phenylalanine residues within putative R6-RVXF motifs were substituted for alanine, allowing us to 
probe the role of the PP1-binding motif in AMPKβ2/R6-binding (Fig. 2B). R6-RARA, a mutant known to 
have lost its capacity to bind to endogenous PP1c but not to PP1-substrates (23), presented a similar 
AMPKβ2-binding profile compared to wild-type, non-mutated R6 (R6-WT; Fig. 2B; right panel). The R6-
RAHA mutant that carried mutations in a domain close to the substrate-binding motif, however, had 
completely lost its ability to interact with AMPK (Fig. 2B; right panel). This data was reproduced in a 
reciprocal Y2H assay using AMPKβ2 as bait (Fig. 2C). Further, the substrate-binding motif (WDNND) 
was mutated to study its effect on AMPKβ2/R6 interaction. In one of the mutants, the two aspartate 
residues present within the WDNND motif were replaced by alanine (R6-WANNA mutant), whereas in 
the R6-WDNAD mutant, the second asparagine residue was replaced by alanine. Whereas the R6-
WDNAD mutant was still capable of interacting with AMPKβ2, the WANNA mutation abolished 
AMPKβ2 binding (Fig. 2B right panel and 2C). In good agreement, Y2H analyses using AMPKβ1 or 
AMPKβ2 as bait confirmed that the binding of R6 to the AMPKβ subunits depended on the R6 substrate-
binding motif being intact (Fig. 2C and 2D). Thus, we show that the AMPKβ/R6 interaction requires the 
R6 substrate-binding motif. In all subsequent experiments, we concentrated on AMPKβ2/R6 interaction. 
 
AMPKβ2 Thr-148 mutant shows reduced interaction with R6 
Previously, we showed that substitution of the glycine-147 residue for arginine (G147R) within the β1-
CBM domain abolished the interaction of AMPK with R6 (20), indicating that AMPKβ1 requires the 
CBM for interaction with R6. More recently, we demonstrated that autophosphorylation at the β-
threonine-148 (Thr-148) residue, centrally located in the CBM, prevents AMPK from binding to 
carbohydrates such as glycogen (22). As we show here that R6 also interacts with AMPKβ2, we next 
investigated whether Thr-148 is required for AMPKβ2/R6 interaction. To this end, a phospho-mimicking 
AMPKβ2 mutant was generated by substituting the threonine-148 residue for aspartate (T148D) within the 
β2-CBM. Transiently transfected HEK293T cells co-expressing FLAG-R6 and AMPK heterotrimers 
(myc-α1 and γ1 in combination with either β2-WT- or β2-T148D-mCherry), were cultured under high 
glucose conditions (25 mM) and used for co-immunoprecipitation analysis. Impaired interaction between 
AMPKβ2 and R6 was observed in cells overexpressing mutant AMPKβ2-T148D (Fig. 3A; right panel); 
relevantly, FLAG-R6 and mCherry-β2 were expressed at comparable levels (Fig. 3A; left panel).  
Independent Y2H analyses corroborated these findings: T148D mutation decreased the interaction 
between AMPKβ2 and R6 (Fig. 3B). Taken together, our data indicate that Thr-148 mutation into 
aspartate results in loss of AMPKβ2/R6 interaction, suggesting that an intact Thr-148 residue is essential 
for the formation of the AMPKβ2/R6 complex under glucose-rich culturing conditions. 
 
  
 Glycogen depletion enhances the interaction between AMPKβ2 and R6 
To investigate whether the interaction between AMPKβ2 and R6 is responsive to variation in glycogen 
level, we aimed to deplete cellular glycogen content. Hence, HEK293T cells were either 
pharmacologically treated with forskolin, a compound inducing glycogen breakdown (31), or glucose-
deprived, after which glycogen content was assessed. Because R6 is known to have glycogenic properties 
(24), we included non-transfected control cells and compared these with cells that were either transfected 
with FLAG-R6 alone, or co-transfected with all three subunits of AMPK (myc-α1, β2-WT-mCherry, γ1). 
As expected, cells overexpressing FLAG-R6 showed high glycogen content (both in the absence and 
presence of overexpressed AMPKβ2 complex): basal glycogen levels were 30 − 40-fold increased 
compared to non-transfected control cells (Fig. 4A). Both forskolin-treatment and glucose-deprivation 
significantly lowered the intracellular glycogen levels in all cell lines, as compared to control (Fig. 4A). 
To assess the effect of cellular glycogen content on AMPKβ2/R6 interaction, HEK293T cells 
overexpressing both FLAG-R6 and AMPKβ2 heterotrimers were either treated with forskolin or glucose-
deprived for 16 h. Reduction of cellular glycogen content, either by forskolin-treatment or glucose-
deprivation, substantially enhanced the interaction between AMPKβ2 and R6 that was accompanied by a 
similar increase in the T172 phosphorylation level (Fig. 4B; right panel); as total levels of AMPK and R6 
did not change within the experimental time frame (Fig. 4B; left panel), this ruled out any possible 
interference by altered expression. Further, we examined whether the binding of overexpressed AMPKβ2 
to FLAG-R6 is reversible (Fig. 4C). Expectedly, immunoprecipitates of AMPK from cells that were 
cultured in low glucose medium displayed clear interaction with R6. When cells were switched back to 
incubation in high glucose medium this association decreased time-dependently resulting in a complete 
loss of the AMPKβ2/R6 interaction after 30 minutes. Collectively, our data suggest that the interaction 
between AMPKβ2 heterotrimers and R6 is dynamic and inversely correlated to cellular glycogen level. 
To independently examine a possible direct effect of glycogen on the AMPKβ2/R6 binding, we 
next used β-cyclodextrin (β-CD), a model-sugar that mimics glycogen, in competitive binding-
immunoprecipitation experiments in HEK293T cells cultured under high glucose. Addition of β-CD 
completely disrupted the interaction between AMPKβ2 and R6 (Fig. 4D; right panel). Combined, these 
data suggest that under glucose-rich conditions glycogen disturbs AMPKβ2/R6 interaction, indicating that 
glycogen interferes with and therefore weakens the interaction between AMPKβ2 and R6.   
 
AMPKβ2/R6 interaction is enhanced by glycogen depletion in conjunction with increased AMPKβ2 
Thr-148 phosphorylation 
Next, we assessed the impact of Thr-148 phosphorylation on the glycogen-modulated AMPKβ2/R6 
interaction. To this end, we co-transfected HEK293T cells with AMPK heterotrimers (myc-α1, γ1, and 
either mCherry-tagged β2-WT or -T148D mutant) and FLAG-R6, and challenged the cells for 16 h with 
various concentrations of glucose. The expression of AMPKβ2-T148D mutant did not affect the 
glycogenic activity of FLAG-R6 in cells cultured under high glucose conditions (Fig. 5A), indicating that 
glycogen production depends on the function of R6 but not on the interaction between R6 and AMPKβ2. 
Reduced availability of glucose (i.e., 3 mM or 0 mM) correlated with significantly decreased intracellular 
levels of glycogen in both AMPKβ2-WT and -T148D expressing cells (Fig. 5A). Interestingly, we 
observed increased levels of Thr-148 phosphorylation in β2-WT immunoprecipitates upon lowering 
glucose conditions, although we did not find changes in the levels of AMPK Thr-172 phosphorylation, 
neither in cellular lysates nor in the precipitates from β2-WT or β2-T148D expressing cells (Fig. 5B). Low 
glycogen content enhanced AMPKβ2/R6 interaction (Fig. 5B; cf. Fig. 4). Whereas AMPKβ2-WT/R6 
binding was readily detectable, T148D mutation completely abolished AMPKβ2 interaction with R6, 
independent of the glycogen status (Fig. 5B; cf. Fig. 3). Further, we investigated the effect of AMPK 
activation on AMPKβ2/R6 interaction using various AMPK activating stimuli (Fig. 5C). Again, 
AMPKβ2-T148D mutant did not associate with R6 in any of the conditions tested. AMPK activation 
generally enhanced AMPKβ2-WT/R6 interaction. Oligomycin exhibited the strongest AMPK activating 
effect (Thr-172 phosphorylation in Fig. 5C; left panel). AMPKβ2 Thr-148 phosphorylation and the 
binding of R6 to AMPKβ2 were greatly enhanced by oligomycin (Fig. 5C; right panel). Next, we exposed 
 cells to oligomycin in the context of high and low cellular glycogen. If glycogen content was low (i.e., 3 
mM glucose), oligomycin activated AMPK (Thr-172 phosphorylation; Fig. 5D), an effect that was 
overruled by high cellular glycogen content (i.e., 25 mM glucose). Oligomycin-induced activation of 
AMPK and the consequential Thr-148 phosphorylation further enhanced the interaction of AMPKβ2-WT 
and R6 (Fig. 5D; right panel) under low glycogen conditions. This interaction was disrupted by high 
cellular glycogen or by T148D mutation (Fig. 5D). These results indicate that glycogen-depletion 
enhances both AMPKβ2/R6 interaction and phosphorylation of Thr-148. Our data also indicate that 
phosphorylation of AMPKβ2 at Thr-148 has a different outcome from AMPKβ2-T148D mutant: whereas 
the AMPKβ2-T148D mutant is not able to interact with R6, AMPKβ2/R6 interaction is improved under 
conditions that enhance AMPKβ2 Thr-148 phosphorylation. 
 
Endogenous AMPKβ2 shows enhanced interaction with R6 upon glycogen depletion in C2C12 
myotubes 
Furthermore, we explored the significance of cellular glycogen with respect to AMPKβ2/R6 interaction in 
C2C12 myotubes, a more physiologically relevant model. Similar to all other tested cell types, 
endogenous R6 was below detection level in C2C12 cells using a variety of available antibodies (data not 
shown). Hence, we stably expressed FLAG-R6 or empty vector (EV) control in C2C12 myoblasts. C2C12 
cells were then differentiated to myotubes and cultured under high (i.e., 25 mM) or low (i.e., 3 mM) 
glucose concentrations prior to oligomycin-treatment. We determined glycogen content and AMPKβ2/R6 
interaction for each condition (Fig. 6A, B). Both lowered glucose availability and oligomycin-treatment 
reduced the myocellular glycogen content below detection level in cells expressing the EV control (Fig. 
6A). R6 overexpression greatly enhanced the levels of glycogen under basal and treated conditions (Fig. 
6A). Oligomycin challenged the glycogen levels (Fig, 6A) and clearly induced AMPK activation in 
C2C12 myotubes, under both high and low glucose conditions (Fig 6B, left panel). However, as in 
HEK293T cells, oligomycin-mediated AMPK activation could only be detected in immunoprecipitates 
from cells that were cultured under low glycogen conditions (Fig. 6B; right panel). As expected, increased 
interaction of AMPKβ2 with R6 was detected after immunoprecipitating FLAG-R6 from oligomycin-
treated cells under low glycogen conditions (Fig. 6B; right panel). By performing the reverse 
immunoprecipitation using AMPKα1/α2-directed antibodies, we also detected enhanced FLAG-R6 
presence in the low glycogen condition (Fig. 6C). Moreover, we detected T148-phosphorylation of 
endogenous AMPKβ2, which expectedly was highest in conjunction with low glycogen in oligomycin-
treated immunoprecipitates (Fig. 6C). We further assessed the presence of Thr-148 phosphorylation in a 
physiological context. Gastrocnemius muscle was obtained from untreated mice and AMPK was 
immunoprecipitated from homogenates (Fig. 6D). As shown by Western blotting, Thr-148 
phosphorylation signal was evident. Decrease of this signal upon incubation with calf intestine 
phosphatase (CIP) further confirms the phosphorylation event. Therefore, skeletal muscle may operate 
signaling pathways involving phosphorylated Thr-148. Taken together, in good agreement with our 
observations in HEKT293 cells, the data obtained from C2C12 myotubes support the notion that cellular 
glycogen content controls AMPKβ2/R6 binding. Also, Thr-148 phosphorylation of endogenous AMPKβ2 
occurred in conjunction with R6 interaction in C2C12 myotubes 
 
AMPKβ2 Thr-148 mutant enhances glycogen content of C2C12 myotubes 
We next studied the effect of expressing AMPKβ2-T148D mutant in C2C12 cells in terms of glucose 
uptake and glycogen accumulation. To this end, we stably expressed AMPKβ2-WT or -T148D mutant in 
C2C12 cells, and after differentiation, cells were incubated in high, low or absence of glucose. 
Expectedly, the glycogen levels were challenged by low or no glucose incubations (Fig. 7A). However, 
relative to WT, the T148D mutant overexpressing cells showed higher glycogen content (under high 
glucose). Since AMPKβ2-T148D mutant does not associate with glycogen (and R6), these data could 
indicate a function of the AMPKβ2-T148D mutant that is independent of the glycogen particle, possibly 
by improving glucose uptake. However, glucose uptake changes were statistically insignificant (Fig. 7B).  
 
  
DISCUSSION 
In the current study, we demonstrate the involvement of Thr-148 in the dynamic AMPKβ2/R6 interaction 
that is governed by glycogen content.  
Due to the positioning of Thr-148 in the carbohydrate-binding pocket, the phosphorylation of this 
residue is incompatible with glycogen binding Glucose deprivation expectedly resulted in reduced 
glycogen levels (Figs. 4-7). Accordingly, we detected strong AMPKβ2 Thr-148 phosphorylation signals 
only when glycogen levels were low, which were further augmented by oligomycin treatment (Fig. 5). 
Similar to GS, which dissociates from glycogen in response to glycogen breakdown (32, 33), decreased 
glycogen content may also cause AMPKβ2 and R6 to leave glycogen. In support of such notion, 
oligomycin-induced AMPK activation augmented AMPKβ2/R6 interaction also in C2C12 myotubes, 
while further depleting glycogen and inducing Thr-148 phosphorylation (Fig. 6), strongly suggesting that 
these events are linked. In conjunction with lowered glycogen content, oligomycin-induced Thr-172 
phosphorylation was also more effective, which ties in with autophosphorylation of Thr-148, i.e., by 
AMPK. Thus, autophosphorylation of Thr-148 by AMPK may indicate detachment of AMPK from 
glycogen in conditions that challenge the cellular glycogen level.  
We find that phosphorylation of AMPKβ2 at Thr-148 enhanced the binding to R6, whereas 
AMPKβ2/R6 interaction was completely lost in the AMPKβ2-T148D mutant. The latter results are in 
agreement with earlier observations, where the AMPKβ1-G147R mutation impaired the ability to interact 
with R6 (20). Since AMPKβ Thr-148 is located adjacent to Gly-147, a similar loss of binding to R6 for the 
Thr-148 mutant was expected. Nevertheless, the molecular mechanism explaining the loss of binding to 
R6 as a result of T148D mutation remains unclear, because Thr-148 phosphorylation was enhanced in 
conjunction with AMPKβ2/R6 interaction (Fig. 5). In our previous study, we found that T148D mutant 
did not bind glycogen (22). Hence, there are at least two possible explanations: (i) the T148D mutation 
causes a subtle modification in the conformation of the β2 subunit resulting in the loss of interaction with 
R6, a process not shared by the physiological phosphorylation of this subunit; or (ii) the interaction of 
AMPKβ2-WT with R6 that is observed during glycogen degradation evolves from their initial binding at 
glycogen. These explanations are not mutually exclusive and we formally cannot rule out the former, but 
there are arguments in support of the latter notion. Firstly, both AMPKβ2 and R6 bind to glycogen via 
their respective CBM (12, 34). The co-localization of AMPK and R6 to glycogen brings them in close 
proximity to each other, which may facilitate their subsequent direct interaction, i.e., as a second step 
during conditions that degrade glycogen. Hence, the possible mechanisms causing AMPKβ2 and R6 to 
leave the dwindling glycogen particle may include the decreasing surface binding options. On a 
diminishing glycogen granule, we can indeed expect the concentration of potential interaction partners to 
increase dramatically, which may facilitate a direct binding between these proteins concomitant with their 
detachment from glycogen. This is in accordance with our findings showing that depletion of intracellular 
glycogen resulted in enhanced AMPKβ2/R6 interaction (Figs. 4-6). In particular, the AMPKβ2/R6 
complex was more abundant in glucose-deprived or forskolin-treated cells (Fig. 4B). Similarly, in earlier 
Y2H analyses, low glucose media augmented the AMPKβ1/R6 interaction (35). Secondly, high glycogen 
content was found to decrease AMPKβ2/R6 interaction (Figs. 4-6), and thus glycogen may in fact rather 
perturb the direct binding between AMPKβ2 and R6. In addition, AMPKβ2/R6 binding decreased upon 
treatment of co-immunoprecipitations with β-CD (Fig. 4D). Since the R6-substrate-binding motif partially 
overlaps with the CBM domain (23), it is conceivable that glycogen competes with R6 binding to AMPK. 
Thus, our data suggest that low glycogen favors AMPKβ2/R6 interaction, whereas high glycogen content 
interferes with it. We propose that the AMPKβ2-T148D mutant, due to lack of glycogen-binding affinity, 
is excluded from the interaction with R6 because this process initiates at glycogen.  
AMPK plays an essential role in various biological processes involved in restoring cellular energy 
homeostasis. Tuning of such processes requires adequate regulation, and involves AMPK 
compartmentalization and complex formation with other proteins and substrates. In the present study, we 
show that R6 preferentially interacts with AMPKβ2, rather than AMPKβ1, pointing to a possible role for 
this interaction in skeletal muscle. The CBM domain of AMPKβ2 possesses higher binding affinity for 
 carbohydrates such as glycogen than β1 (14). In a more detailed study the CBM domain of AMPKβ2 
bound linear carbohydrates and single α1,6-branched carbohydrates 4-30 fold tighter in comparison with 
β1 (36). AMPKβ2, as well as R6, are highly expressed in skeletal muscle (3, 37), a tissue active in 
controlling disposal of glucose into glycogen (38). Thus, it is likely that these proteins contribute to the 
regulation of myocellular glycogen turnover. Recent in vivo studies seemingly contradict the importance 
of AMPKβ2 in glycogen metabolism: The observed differences in glycogen content were marginal 
between WT and AMPKβ1/β2 double knockout mice pre- and post-exercise (39). In AMPKβ2 knockout 
mice, muscular glycogen content was reduced pre-exercise and was equal with a slight tendency to 
increase post-exercise (6, 7). However, since there is a reduction in the levels of skeletal muscle AMPKα1 
and α2 in β2 knockout mice and a dramatic reduction of the levels of the AMPK complex subunits in 
double AMPKβ1/β2 knockout mice, it is difficult to make any correlation between the levels of glycogen 
in these mice and the activity of AMPK. We recently showed that activation of AMPK precedes AMPKβ 
Thr-148 autophosphorylation to preclude the AMPK complex from binding to glycogen and further data 
suggested a possible role for Thr-148 phosphorylation in glycogen turnover in several cell lines (22). 
Thus, independent of possible functions for AMPK complexes that are bound at glycogen particles, free 
cytosolic AMPK may also indirectly affect glycogen metabolism, as further supported by T148D 
overexpression in C2C12 myotubes (Figure 7). Moreover, R6 is a known glycogen-binding protein and 
PP1-targeting subunit acting as a glycogenic driver (24). Hence, it is conceivable to expect that 
AMPKβ2/R6 interaction is playing an important role in glycogen metabolism in muscle.  
In yeast, it was reported earlier that Gal83 (Snf1 β-subunit ortholog) is involved in binding to 
Reg1 (PP1 glycogenic subunit ortholog) and studies in mouse pancreatic β cells revealed that AMPKβ1 
interacts with the PP1-glycogen targeting subunit R6 (20, 40). R6 recruits PP1 phosphatase to its 
substrates (e.g., GS and GP) (23), thus playing a critical role in the regulation of glycogen metabolism. 
Most of the PP1-glycogen-targeting subunits exert their actions through binding to PP1 via a conserved N-
terminal PP1-binding motif (RVXF), and interact with PP1-substrates via a conserved C-terminal 
substrate-binding (WXNXGNYX(L/I)) motif (23). We have recently shown that R6 utilizes this conserved 
region to bind to its glycogenic substrates GS and GP (23). In line with these results, our work indicates 
that AMPKβ/R6 interaction occurs also via the R6 substrate-binding motif (Fig. 2), as a mutation in this 
domain resulted in loss of interaction, a process that is independent of PP1 binding. However, we did not 
find evidence for R6/PP1-dependent AMPK dephosphorylation in our study under conditions where 
AMPKβ2/R6 interaction was enhanced. This may be attributed to the use of glycogen depletion and 
mitochondrial poisoning as triggers. Although we find these treatments as required to induce significant 
AMPKβ2/R6 interaction, their application necessarily goes along with elevated AMP levels and 
consequent protection from Thr-172 dephosphorylation (41). In MIN6 pancreatic β-cells, the R6/PP1 
complex was responsible for AMPK dephosphorylation at Thr-172 in response to high extracellular 
glucose (20). In HEK293 cells, we find that glucose re-availability leads to a transient decrease of Thr-172 
phosphorylation (Fig. 4C). In the same experiment, AMPKβ2/R6 interaction disappeared time-
dependently after recovery with high glucose. Hence, the idea that R6 could act as a scaffold to bring 
AMPKβ2 in close proximity to the PP1 phosphatase warrants further investigation. The present data 
establish that AMPKβ2/R6 complex formation and dissociation are reversible and dynamic processes that 
involve the substrate-binding site of R6. Taken together, we shed new light on the molecular events that 
govern the interaction of AMPK with R6.  
 
ACKNOWLEDGMENTS 
We thank the members of the Molecular Genetics department of Maastricht University for helpful 
comments and support.  
 
DECLARATIONS OF INTEREST 
The authors declare that they have no conflicts of interest with the contents of this article. 
 
  
 AUTHOR CONTRIBUTIONS 
Yvonne Oligschlaeger, Marie Miglianico, Vivian Dahlmans, Carla Rubio-Villena, Dipanjan Chanda, 
Maria Adelaida Garcia-Gimeno, Will Coumans, Yilin Liu, Pascual Sanz and Dietbert Neumann designed 
and carried out the experiments. Yvonne Oligschlaeger, Pascual Sanz and Dietbert Neumann wrote the 
manuscript. Jan Willem Voncken, Joost Luiken and Jan Glatz contributed with material, provided 
conceptual input and assisted in the manuscript preparation. All authors reviewed the results and approved 
the final version of the manuscript.  
 
FUNDING 
DN is recipient of a VIDI-Innovational Research Grant from the Netherlands Organization of Scientific 
Research (NWO-ALW Grant no. 864.10.007). This work has further been supported by grants from the 
Spanish Ministry of Education and Science SAF2014-54604-C3-1-R and a grant from Generalitat 
Valenciana (PrometeoII/2014/029) to PS. 
 
 
REFERENCES 
1. Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis 
of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. 
Annu Rev Nutr. 2010;30:273-90. 
2. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5' AMP-activated protein kinase 
activation causes GLUT4 translocation in skeletal muscle. Diabetes. 1999;48(8):1667-71. 
3. Thornton C, Snowden MA, Carling D. Identification of a novel AMP-activated protein kinase 
beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem. 1998;273(20):12443-50. 
4. Chen Z, Heierhorst J, Mann RJ, Mitchelhill KI, Michell BJ, Witters LA, et al. Expression of the 
AMP-activated protein kinase beta1 and beta2 subunits in skeletal muscle. FEBS Lett. 1999;460(2):343-8. 
5. Dzamko N, van Denderen BJ, Hevener AL, Jorgensen SB, Honeyman J, Galic S, et al. AMPK 
beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J Biol Chem. 
2010;285(1):115-22. 
6. Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, et al. The AMPK beta2 subunit is 
required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012;32(14):2837-48. 
7. Steinberg GR, O'Neill HM, Dzamko NL, Galic S, Naim T, Koopman R, et al. Whole body 
deletion of AMP-activated protein kinase {beta}2 reduces muscle AMPK activity and exercise capacity. J 
Biol Chem. 2010;285(48):37198-209. 
8. McGee SL, Howlett KF, Starkie RL, Cameron-Smith D, Kemp BE, Hargreaves M. Exercise 
increases nuclear AMPK alpha2 in human skeletal muscle. Diabetes. 2003;52(4):926-8. 
9. Kodiha M, Rassi JG, Brown CM, Stochaj U. Localization of AMP kinase is regulated by stress, 
cell density, and signaling through the MEK-->ERK1/2 pathway. Am J Physiol Cell Physiol. 
2007;293(5):C1427-36. 
10. Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-
activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-
methylglutaryl-CoA reductase kinase activities. Eur J Biochem. 1989;186(1-2):129-36. 
11. Kazgan N, Williams T, Forsberg LJ, Brenman JE. Identification of a nuclear export signal in the 
catalytic subunit of AMP-activated protein kinase. Mol Biol Cell. 2010;21(19):3433-42. 
12. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, et al. AMPK β Subunit 
Targets Metabolic Stress Sensing to Glycogen. Current Biology. 2003;13(10):867-71. 
13. Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, et al. A Novel Domain in 
AMP-Activated Protein Kinase Causes Glycogen Storage Bodies Similar to Those Seen in Hereditary 
Cardiac Arrhythmias. Current Biology. 2003;13(10):861-6. 
14. Koay A, Woodcroft B, Petrie EJ, Yue H, Emanuelle S, Bieri M, et al. AMPK beta subunits 
display isoform specific affinities for carbohydrates. FEBS Lett. 2010;584(15):3499-503. 
 15. Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, Richter EA. Glycogen-dependent effects 
of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen 
synthase activities in rat skeletal muscle. Diabetes. 2002;51(2):284-92. 
16. Hunter RW, Treebak JT, Wojtaszewski JF, Sakamoto K. Molecular mechanism by which AMP-
activated protein kinase activation promotes glycogen accumulation in muscle. Diabetes. 2011;60(3):766-
74. 
17. Fong NM, Jensen TC, Shah AS, Parekh NN, Saltiel AR, Brady MJ. Identification of binding sites 
on protein targeting to glycogen for enzymes of glycogen metabolism. J Biol Chem. 2000;275(45):35034-
9. 
18. Heroes E, Lesage B, Gornemann J, Beullens M, Van Meervelt L, Bollen M. The PP1 binding 
code: a molecular-lego strategy that governs specificity. FEBS J. 2013;280(2):584-95. 
19. Armstrong CG, Browne GJ, Cohen P, Cohen PTW. PPP1R6, a novel member of the family of 
glycogen-targetting subunits of protein phosphatase 1. FEBS Letters. 1997;418(1-2):210-4. 
20. Garcia-Haro L, Garcia-Gimeno MA, Neumann D, Beullens M, Bollen M, Sanz P. The PP1-R6 
protein phosphatase holoenzyme is involved in the glucose-induced dephosphorylation and inactivation of 
AMP-activated protein kinase, a key regulator of insulin secretion, in MIN6 beta cells. FASEB J. 
2010;24(12):5080-91. 
21. Sanz P, Alms GR, Haystead TA, Carlson M. Regulatory interactions between the Reg1-Glc7 
protein phosphatase and the Snf1 protein kinase. Mol Cell Biol. 2000;20(4):1321-8. 
22. Oligschlaeger Y, Miglianico M, Chanda D, Scholz R, Thali RF, Tuerk R, et al. The Recruitment 
of AMP-activated Protein Kinase to Glycogen Is Regulated by Autophosphorylation. J Biol Chem. 
2015;290(18):11715-28. 
23. Rubio-Villena C, Sanz P, Garcia-Gimeno MA. Structure-Function Analysis of PPP1R3D, a 
Protein Phosphatase 1 Targeting Subunit, Reveals a Binding Motif for 14-3-3 Proteins which Regulates its 
Glycogenic Properties. PLoS One. 2015;10(6):e0131476. 
24. Rubio-Villena C, Garcia-Gimeno MA, Sanz P. Glycogenic activity of R6, a protein phosphatase 1 
regulatory subunit, is modulated by the laforin-malin complex. Int J Biochem Cell Biol. 2013;45(7):1479-
88. 
25. Gimeno-Alcaniz JV, Sanz P. Glucose and type 2A protein phosphatase regulate the interaction 
between catalytic and regulatory subunits of AMP-activated protein kinase. J Mol Biol. 2003;333(1):201-
9. 
26. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant 
retrovirus. Hum Gene Ther. 1996;7(12):1405-13. 
27. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with 
multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 
1990;18(12):3587-96. 
28. Voncken JW, Niessen H, Neufeld B, Rennefahrt U, Dahlmans V, Kubben N, et al. MAPKAP 
kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J 
Biol Chem. 2005;280(7):5178-87. 
29. Schwenk RW, Dirkx E, Coumans WA, Bonen A, Klip A, Glatz JF, et al. Requirement for distinct 
vesicle-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced 
translocation of GLUT4 and CD36 in cultured cardiomyocytes. Diabetologia. 2010;53(10):2209-19. 
30. Skehel JM. Preparation of extracts from animal tissues. Methods Mol Biol. 2004;244:15-20. 
31. Singh PK, Singh S, Ganesh S. The laforin-malin complex negatively regulates glycogen synthesis 
by modulating cellular glucose uptake via glucose transporters. Mol Cell Biol. 2012;32(3):652-63. 
32. Nielsen JN, Derave W, Kristiansen S, Ralston E, Ploug T, Richter EA. Glycogen synthase 
localization and activity in rat skeletal muscle is strongly dependent on glycogen content. J Physiol. 
2001;531(Pt 3):757-69. 
33. Prats C, Cadefau JA, Cusso R, Qvortrup K, Nielsen JN, Wojtaszewski JF, et al. Phosphorylation-
dependent translocation of glycogen synthase to a novel structure during glycogen resynthesis. J Biol 
Chem. 2005;280(24):23165-72. 
 34. Machovic M, Janecek S. Starch-binding domains in the post-genome era. Cell Mol Life Sci. 
2006;63(23):2710-24. 
35. Garcia-Haro L, Garcia-Gimeno MA, Neumann D, Beullens M, Bollen M, Sanz P. Glucose-
dependent regulation of AMP-activated protein kinase in MIN6 beta cells is not affected by the protein 
kinase A pathway. FEBS Lett. 2012;586(23):4241-7. 
36. Mobbs JI, Koay A, Di Paolo A, Bieri M, Petrie EJ, Gorman MA, et al. Determinants of 
oligosaccharide specificity of the carbohydrate-binding modules of AMP-activated protein kinase. 
Biochem J. 2015;468(2):245-57. 
37. Montori-Grau M, Guitart M, Garcia-Martinez C, Orozco A, Gomez-Foix AM. Differential pattern 
of glycogen accumulation after protein phosphatase 1 glycogen-targeting subunit PPP1R6 overexpression, 
compared to PPP1R3C and PPP1R3A, in skeletal muscle cells. BMC Biochem. 2011;12:57. 
38. Ren JM, Marshall BA, Gulve EA, Gao J, Johnson DW, Holloszy JO, et al. Evidence from 
transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal 
muscle. J Biol Chem. 1993;268(22):16113-5. 
39. O'Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jorgensen SB, Schertzer JD, et al. AMP-
activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in 
maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci U S A. 
2011;108(38):16092-7. 
40. Mangat S, Chandrashekarappa D, McCartney RR, Elbing K, Schmidt MC. Differential roles of 
the glycogen-binding domains of beta subunits in regulation of the Snf1 kinase complex. Eukaryot Cell. 
2010;9(1):173-83. 
41. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5'-
AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol 
Chem. 2006;281(43):32207-16. 
 
 
  
 FIGURE LEGENDS 
 
Figure 1. R6 preferentially interacts with AMPKβ2 
(A and B) HEK293T cells transiently overexpressing FLAG-R6 and heterotrimers of AMPKβ1 (myc-α1, 
γ1, AMPKβ1-mCherry) (A) or AMPKβ2 (myc-α1, γ1, AMPKβ2-mCherry) (B). FLAG empty vector (EV) 
was used as control. Cells were continuously cultured under high glucose (25 mM) conditions and 
harvested 56 h post-transfection. Interaction between AMPKβ1/2 and R6 was assessed by 
immunoprecipitating the heterotrimeric AMPK complex from 800 μg of lysate using the anti-myc-tag 
antibody. Western blots were assessed using the indicated antibodies. Representative Western blots are 
shown. (C) Yeast THY-AP4 strain (see Materials and Methods) was transformed with the indicated 
combination of plasmids. Transformants were grown in high glucose (4 % glucose) containing medium 
and protein interactions were estimated by measuring the β-galactosidase activity. Empty vector pGADT7 
(GAD-Φ) served as control. Values correspond to means from at least 6 different transformants (bars 
indicate S.D.). * p<0.001 vs. LexA-AMPKβ1-WT + GAD-R6. 
 
Figure 2. R6 interaction with AMPKβ2 requires its substrate-binding motif 
(A) Schematic model indicating the PP1- and substrate-binding sites of R6, and its corresponding 
mutations. (B) HEK293T cells transiently co-expressing AMPKβ2 heterotrimers (myc-α1, γ1, AMPKβ2-
mCherry) and FLAG-R6 wild-type (R6-WT) or mutant (R6-RARA, R6-RAHA, R6-WANNA, R6-
WDNAD, respectively) were continuously cultured under high glucose (25 mM) conditions and harvested 
48 h post-transfection. FLAG empty vector (EV) was used as control. Interaction between AMPKβ2 and 
R6 was assessed by immunoprecipitating the heterotrimeric AMPK complex from 450 μg of lysate using 
the anti-myc-tag antibody. Western blots were assessed using the indicated antibodies. Representative 
Western blots are shown. (C and D) Yeast THY-AP4 strain (see Materials and Methods) was transformed 
with GAD-AMPKβ2 (C) or GAD-AMPKβ1 (D) plasmids and LexA-R6 plasmids as indicated. 
Transformants were grown in high glucose (4 % glucose) containing medium and protein interactions 
were estimated by measuring the β-galactosidase activity. Values correspond to means from at least 6 
different transformants (bars indicate S.D.). * p<0.05 and ** p<0.001 vs. LexA-R6-WT. 
 
Figure 3. AMPKβ2 Thr-148 mutant shows reduced interaction with R6 
(A) HEK293T cells transiently transfected with myc-α1, γ1 and mCherry-tagged AMPKβ2 wild-type 
(WT) or Thr-148 mutant (T148D) were co-transfected either with FLAG-R6 (+), or FLAG empty vector (-
) as control. Cells were cultured under high glucose (25 mM) conditions, and harvested 56 h post-
transfection. Interaction between AMPKβ2 and R6 was assessed by immunoprecipitating the 
heterotrimeric AMPK complex from 800 μg of lysate using the anti-myc-tag antibody. Western blots were 
assessed using the indicated antibodies. Representative Western blots are shown. (B) Yeast THY-AP4 
strain was transformed with plasmids LexA-AMPKβ2-WT or LexA-AMPKβ2-T148D and GAD-R6 as 
indicated. Transformants were grown in high glucose (4 % glucose) containing medium and protein 
interactions were estimated by measuring the β-Galactosidase activity. Empty vector pGADT7 (GAD-Ф) 
served as control. Values correspond to means from at least 6 different transformants (bars indicate S.D.). 
* p<0.001 vs. LexA-AMPKβ2-WT + GAD-R6. 
 
Figure 4. Glycogen depletion enhances the interaction between AMPKβ2 and R6 
(A and B) HEK293T cells either non-transfected, transiently transfected with FLAG-R6 alone, or co-
transfected with FLAG-R6, myc-α1, γ1 and mCherry-tagged AMPKβ2-WT were cultured under high 
glucose (25 mM) conditions. Prior to lysis, cells were treated with forskolin (100 μM) or DMSO (control) 
under high glucose conditions, or cells were glucose-deprived (GD, 0 mM) for 16 h. (A) Intracellular 
glycogen level was determined as described in the section Materials and Methods. Levels were corrected 
for corresponding protein concentrations. * p<0.05 vs. corresponding DMSO controls; n=2. (B) 
Heterotrimeric AMPK was immunoprecipitated from 500 μg of lysate using the anti-myc-tag antibody, 
followed by Western blot analysis using the indicated antibodies. (C) HEK293T cells transiently 
 transfected with FLAG-R6, myc-α1, γ1 and mCherry-tagged AMPKβ2-WT were cultured under low 
glucose (3 mM) conditions and recovered with high glucose medium for the indicated time period before 
lysis and immunoprecipation. (D) HEK293T cells were transiently co-transfected as indicated and 
harvested 56 h post-transfection. Cells were continuously grown under high glucose (25 mM) conditions. 
β-Cyclodextrin (β-CD; 5 mM) was added prior to immunoprecipitation. Representative Western blots are 
shown. 
 
Figure 5. AMPKβ2/R6 interaction is enhanced in conjunction with increased AMPKβ2 Thr-148 
phosphorylation 
HEK293T cells were transiently transfected for co-expression of AMPKβ2 heterotrimers (myc-α1, γ1, 
mCherry-tagged AMPKβ2-WT or -T148D) and FLAG-R6. (A and B) Prior to lysis, cells were cultured 
under various glucose conditions (i.e., 25 mM, 3 mM, 0 mM) for 16 h. (A) Intracellular glycogen levels 
were biochemically determined and corrected for the corresponding protein concentrations. * p<0.01 vs. 
WT 25 mM, # p<0.01 vs. T148D 25 mM, ## p<0.001 vs. T148D 25 mM; n=2. (B) Heterotrimeric AMPK 
was immunoprecipitated from 350 μg of lysate using the anti-myc-tag antibody, followed by Western blot 
analysis using the indicated antibodies. (C) Cells were either maintained in growth medium (GM) or 
serum- starved (5.5 mM glucose) for 16 h and treated with vehicle (DMSO) or a variety of AMPK 
activators for 1 h as indicated. AMPK complexes were immunoprecipitated from 350 μg of lysate using 
the anti-myc-tag antibody, followed by Western blot analysis using various antibodies. (D) Cells were 
serum-starved both under low (3 mM) and high (25 mM) glucose conditions for 16 h, prior to 1 h 
treatment with oligomycin (3 μM) or DMSO (control). AMPK was immunoprecipitated from 500 μg of 
lysate as described in panel B, followed by Western blot analysis using the indicated antibodies. 
Representative Western blots are shown. 
 
Figure 6. Endogenous AMPKβ2 shows enhanced interaction with R6 upon glycogen depletion in 
C2C12 myotubes 
C2C12 cells stably overexpressing FLAG-R6 were differentiated into myotubes for 4-5 days, and 
subsequently incubated with high (25 mM) or low (3 mM) glucose for 16 h, followed by 30 minutes 
treatment with oligomycin (5 μM) or DMSO (control). pBabe-puromycin empty vector (EV) was used as 
control. (A) Myocellular glycogen levels were determined using biochemical glycogen assay, as described 
in Materials and Methods. * p<0.05, ** p<0.01, *** p<0.001; n=3. (B) Interaction between AMPKβ2 and 
R6 was assessed by immunoprecipitation using the anti-FLAG-tag antibody, followed by Western blot 
analysis using the indicated antibodies. (C) Interaction between AMPKβ2 and R6 was assessed by 
immunoprecipitation using anti-AMPKα1/α2 antibodies, followed by Western blot analysis using the 
indicated antibodies. (D) Mouse gastrocnemius muscle lysate was cleared by centrifugation and subjected 
to immunoprecipitation using AMPK α1/α2 antibodies. Immunoprecipitates were maintained on ice either 
untreated or treated with calf intestine phosphatase (CIP) and then probed by Western blotting using 
indicated antibodies. Representative Western blots are shown.  
 
Figure 7. AMPKβ2 Thr-148 mutant enhances glycogen content of C2C12 myotubes 
C2C12 cells stably overexpressing AMPKβ2-WT or -T148D mutant were differentiated into myotubes for 
4-5 days, and subsequently incubated with high (25 mM), low (3 mM) or no (0 mM) glucose for 16 h. (A) 
Myocellular glycogen levels were determined using biochemical glycogen assay, as described in Materials 
and Methods. * p<0.01 vs. WT 25 mM, # p<0.05 vs. T148D, $ p<0.05, 25 mM,; n=2. (B) Insulin-
stimulated glucose uptake was determined as described in Material and Methods. $ p<0.01 vs. WT.  
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